KC Pharmaceuticals
Tracked across 30 events · 369 articles · First seen May 07, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The KC Pharmaceuticals issued new advice warning against prolonged use of nasal decongestant sprays.
Jan 08, 2026 · 6 articles
Business
Impact: KC Pharmaceuticals will participate in two investor conferences in June 2026, providing an opportunity to engage with investors and potentially increase visibility and investor interest in the company.
May 27, 2026 · 6 articles
Regulatory
Impact: Initiator of the recall; faces potential reputational damage and financial liability.
Jul 24, 2026 · 12 articles
Business
Impact: Supernus is a merging party, contributing its CNS portfolio and CEO. Its shareholders receive Indivior shares, and the combined entity retains its name and ticker, with shares rising on the announcement.
Aug 03, 2026 · 6 articles
Domestic
Impact: KC Pharmaceuticals accepted the resignation of its finance head, Rajkumar Bafna, due to India — Delhi's air pollution, highlighting potential challenges in retaining talent in affected regions.
Dec 28, 2025 · 11 articles
Tech
Impact: KC Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science Company, is a key collaborator in the siRNA partnership with KC Pharmaceuticals, Inc., successfully reaching a drug nomination milestone for MASH therapies.
Jul 02, 2026 · 7 articles
Business
Impact: Azurity gains exclusive commercialization rights to D-PLEX100 in the U.S. and Canada, expanding its specialty pharmaceutical portfolio. It will fund clinical development for label expansion, positioning for future revenue.
Jul 21, 2026 · 7 articles
Tech
Impact: As Ribo's subsidiary focused on global development, Ribocure is instrumental in executing the clinical trials and will lead further development of vortosiran.
Jul 22, 2026 · 8 articles
Regulatory
Impact: As the parent company of Unique Pharmaceutical Laboratories, KC Pharmaceuticals faces potential reputational damage and scrutiny over manufacturing quality control.
Jul 21, 2026 · 7 articles
Business
Impact: KC Pharmaceuticals>>> is a key company in the pre-filled syringe market, contributing to its expansion.
May 25, 2026 · 6 articles
Business
Nxera Pharma reported its consolidated results for the second quarter ended 30 June 2026, showing a significant improvement in financial performance. Revenue increased to JPY 18,910 million (US$119.6 million), up from JPY 15,095 million in…
Impact: Centessa was acquired by Eli Lilly, completing a transaction that validates the value of its orexin receptor agonist programs. Nxera retains rights to future payments from these programs.
Aug 07, 2026 · 6 articles
Business
Impact: KC Pharmaceuticals is one of the publicly traded companies presenting at the conference, seeking to attract investors and showcase its innovations.
Apr 02, 2026 · 7 articles
Tech
A phase 1 clinical trial of mKRAS-VAX, an investigational vaccine targeting six common KRAS mutations, demonstrated safety and durable immune responses in 18 of 20 high-risk individuals for pancreatic ductal adenocarcinoma (PDAC). The vaccine, developed…
Impact: Licensee of the vaccine technology; positive trial results could increase its valuation and attract investment.
Jul 16, 2026 · 21 articles
International
Impact: KC Pharmaceuticals is vertically integrating the entire supply chain for authentic herbs, accelerating the global expansion of Chinese TCM and heritage wellness brands.
Jun 15, 2026 · 87 articles
Domestic
Impact: Professor Claire Anderson, president of the KC Pharmaceuticals, affirms the safety of paracetamol use during pregnancy, citing extensive safe use and recent studies.
Sep 22, 2025 · 7 articles
International
Impact: Added to the UFLPA Entity List, restricting its pharmaceutical exports to the U.S.
Jul 31, 2026 · 20 articles
Regulatory
Impact: The KC Pharmaceuticals is involved in the establishment of joint oversight committees with the Nigeria — National Drug Law Enforcement Agency to strengthen monitoring of regulated medicines and improve intelligence sharing.
Jun 26, 2026 · 7 articles
Business
Impact: KC Pharmaceuticals became a new shareholder in Adani Group as part of the acquisition settlement.
Jul 02, 2026 · 6 articles
Business
ABL Group and Ascend Advanced Therapies, operating together as ABL Ascend Advanced Therapies, announced the appointment of Suman Subramanian as Chief Business Officer (CBO) on August 10, 2026. Subramanian brings nearly two decades of experience…
Impact: KC Pharmaceuticals is mentioned as a previous employer of Suman Subramanian, providing context to his experience.
Aug 10, 2026 · 6 articles
Business
Lobe Sciences, a clinical-stage biopharmaceutical company, announced and closed a non-brokered private placement of 24,705,880 common shares at $0.085 per share, raising approximately $2.1 million. The proceeds will be used for working capital, general corporate…
Impact: KC Pharmaceuticals, 64% owned by Lobe, is mentioned as a subsidiary developing L-130 for neurological disorders. The private placement is not directly allocated to Cynaptec, but the company benefits from Lobe's overall financial health.
Aug 12, 2026 · 7 articles
Regulatory
Prestige Brands Holdings voluntarily recalled 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops nationwide due to a lack of assurance of sterility and potential contamination. The recall was initiated on July 29,…
Impact: Mentioned as a prior recaller; context for industry-wide sterility issues.
Aug 20, 2026 · 12 articles
Business
Impact: KC Pharmaceuticals is a majority-owned subsidiary of Lobe Sciences and is mentioned as part of Lobe's strategic development, though not directly impacted by this specific private placement.
Apr 11, 2026 · 7 articles
Business
Impact: Adamas Pharmaceuticals>>> was sold to KC Pharmaceuticals>>>.
May 19, 2026 · 6 articles
Accidents
Impact: Mentioned as one of the healthcare companies recently affected by cyberattacks, highlighting sector-wide vulnerability.
Jul 31, 2026 · 6 articles
Business
Impact: KC Pharmaceuticals was acquired by AstraZeneca, serving as a comparable deal in the radiopharmaceutical sector.
Aug 03, 2026 · 7 articles
Business
Tata Capital Healthcare Fund III (TCHF III), the healthcare-focused private equity fund of Tata Sons — Tata Sons, and Switzerland-based impact investor Blue Earth Capital AG have invested approximately $30 million in Tenet Medcorp Private…
Impact: Portfolio company of Tata Capital Healthcare Fund II; mentioned as part of the fund's track record.
Aug 17, 2026 · 6 articles
Regulatory
Impact: KC Pharmaceuticals was involved in a prior unrelated eye drop recall; mentioned for context but not directly affected.
Jul 07, 2026 · 38 articles
Business
Impact: KC Pharmaceuticals was acquired by AbbVie in 2024 for an experimental psychedelic depression therapy, illustrating the competitive landscape.
Jul 16, 2026 · 25 articles
ERGEN INTELLIGENCE
Track KC Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard